121 related articles for article (PubMed ID: 2045293)
1. ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313.
Cox JD; Pajak TF; Marcial VA; Coia L; Mohiuddin M; Fu KK; Selim H; Rubin P; Ortiz H
Int J Radiat Oncol Biol Phys; 1991 Jun; 20(6):1191-5. PubMed ID: 2045293
[TBL] [Abstract][Full Text] [Related]
2. Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13.
Cox JD; Pajak TF; Marcial VA; Hanks GE; Mohiuddin M; Fu KK; Byhardt RW; Rubin P
Int J Radiat Oncol Biol Phys; 1990 Mar; 18(3):515-21. PubMed ID: 2180866
[TBL] [Abstract][Full Text] [Related]
3. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13.
Fu KK; Pajak TF; Marcial VA; Ortiz HG; Rotman M; Asbell SO; Coia LR; Vora NL; Byhardt R; Rubin P
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):577-88. PubMed ID: 7790242
[TBL] [Abstract][Full Text] [Related]
4. Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol 8313.
Cox JD; Pajak TF; Marcial VA; Coia L; Mohiuddin M; Fu KK; Selim HM; Byhardt RW; Rubin P; Ortiz HG
Cancer; 1992 Jun; 69(11):2744-8. PubMed ID: 1571904
[TBL] [Abstract][Full Text] [Related]
5. [Accelerated hyperfractionated radiotherapy combined with simultaneous chemotherapy in locally advanced pharyngeal and oral carcinomas].
Stuschke M; Budach V; Dinges S; Jahnke K; Budach W; Heselmann I; Unger A; Stüben G; Sack H
Strahlenther Onkol; 1994 Dec; 170(12):689-99. PubMed ID: 7817270
[TBL] [Abstract][Full Text] [Related]
6. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ
Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
[TBL] [Abstract][Full Text] [Related]
8. Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG).
Marcial VA; Pajak TF; Chang C; Tupchong L; Stetz J
Int J Radiat Oncol Biol Phys; 1987 Jan; 13(1):41-7. PubMed ID: 3542916
[TBL] [Abstract][Full Text] [Related]
9. N2 (clinical) non-small cell carcinoma of the lung: prospective trials of radiation therapy with total doses 60 Gy by the Radiation Therapy Oncology Group.
Cox JD; Azarnia N; Byhardt RW; Shin KH; Emami B; Perez CA
Int J Radiat Oncol Biol Phys; 1991 Jan; 20(1):7-12. PubMed ID: 1847128
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
Cox JD; Azarnia N; Byhardt RW; Shin KH; Emami B; Pajak TF
J Clin Oncol; 1990 Sep; 8(9):1543-55. PubMed ID: 2167952
[TBL] [Abstract][Full Text] [Related]
11. Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules.
Garden AS; Morrison WH; Ang KK; Peters LJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):493-502. PubMed ID: 7852111
[TBL] [Abstract][Full Text] [Related]
12. Tolerance of pelvic normal tissues to hyperfractionated radiation therapy: results of Protocol 83-08 of the Radiation Therapy Oncology Group.
Cox JD; Guse C; Asbell S; Rubin P; Sause WT
Int J Radiat Oncol Biol Phys; 1988 Dec; 15(6):1331-6. PubMed ID: 3058657
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
14. Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28.
Epstein BE; Scott CB; Sause WT; Rotman M; Sneed PK; Janjan NA; Davis LW; Selim H; Mohiuddin M; Wasserman TH
Cancer; 1993 Feb; 71(4):1362-7. PubMed ID: 8435812
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma.
Pinto LH; Canary PC; Araújo CM; Bacelar SC; Souhami L
Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):557-62. PubMed ID: 1869454
[TBL] [Abstract][Full Text] [Related]
16. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Nelson DF; Curran WJ; Scott C; Nelson JS; Weinstein AS; Ahmad K; Constine LS; Murray K; Powlis WD; Mohiuddin M
Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):193-207. PubMed ID: 8380567
[TBL] [Abstract][Full Text] [Related]
17. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer.
Beitler JJ; Zhang Q; Fu KK; Trotti A; Spencer SA; Jones CU; Garden AS; Shenouda G; Harris J; Ang KK
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):13-20. PubMed ID: 24613816
[TBL] [Abstract][Full Text] [Related]
18. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
Komaki R; Scott CB; Sause WT; Johnson DH; Taylor SG; Lee JS; Emami B; Byhardt RW; Curran WJ; Dar AR; Cox JD
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):537-44. PubMed ID: 9336129
[TBL] [Abstract][Full Text] [Related]
19. Accelerated radiation therapy, seven fractions per week, for advanced head and neck cancer--a feasibility study.
O'Sullivan JM; Hollywood DP; Cody N; Dillon J; Buckney S; Moriarty MJ; Armstrong JG
Clin Oncol (R Coll Radiol); 2002 Jun; 14(3):236-40. PubMed ID: 12109829
[TBL] [Abstract][Full Text] [Related]
20. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
